Department of Microbiology, University of Virginia, HSC, Box 441, 1300 Jefferson Park Avenue, Charlottesville, VA 22908, USA
1 Cancer Biology Program, Division of HematologyOncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
Correspondence to: U. Lorenz
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Keywords: DO11.10 TCR, protein kinases/phosphatases, signal transduction, T lymphocytes, TCR, transgenic mice
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
TCR-initiated signaling pathways play a critical role in determining thymocyte fate during development. The major developmental stages of immature T cells in the thymus are defined by the cell surface expression of the TCR and the co-receptors CD4 and CD8. Immature pre-thymocytes (which originate in the bone marrow) colonize the thymus and first differentiate into `triple-negative' thymocytes that do not express the TCR, CD4 or CD8. These cells then acquire low levels of TCR expression without the expression of CD4 or CD8 [double-negative (DN)]. Via a TCR+CD4CD8low transitional stage, DN thymocytes differentiate into a double-positive (DP) state, in which both CD4 and CD8 are co-expressed with the TCR. DP thymocytes undergo either positive selection (which leads to further maturation and proliferation of selected cells), culminating in the production of CD4+ or CD8+ single-positive (SP) cells, or negative selection (which leads to cell death). In addition to these major stages in T cell differentiation, a number of intermediate states of thymocyte development have also been defined based on the expression of other surface molecules (reviewed in 3,4).
The different stages of T cell maturation in the thymus have been elegantly studied in TCR transgenic mice (TCR Tg) carrying specific TCR and ß chains (reviewed in 5). The introduced TCR genes, which are expressed on almost all immature T cells, as well as on the majority of the mature T cells, provide a convenient approach for following the fate of thymocytes and mature T cells during development. Current models suggest that the TCR of an immature thymocyte interacts with a putative endogenous antigen (presented by thymic epithelial cells) and that the avidity of this T cellantigen interaction determines the fate of the maturing thymocyte. Immature T cells with TCR that have a negligible or low avidity will die due to `neglect'. Thymocytes that express TCR of moderate avidity will be positively selected for further maturation, while those expressing TCR of high avidity for the endogenous antigens will be negatively selected (`deleted') (68).
Mice with specific defects in signaling molecules have provided powerful tools to examine the function of these molecules in T cell development, in particular when crossed with TCR Tg mice. For example, mice with targeted disruption of the genes encoding Lck (9) or the tyrosine phosphatase CD45 (10), which regulates Lck, display blocks in thymocyte development, indicating the importance of these molecules as positive regulators of T cell maturation. Conversely, crosses between the TCR Tg and CD5-deficient mice identified CD5 as a negative regulator of thymocyte selection process (11).
Although much is known about the initiation of the TCR-mediated signaling events, very little is known about mechanism(s) by which TCR signaling is terminated. The tyrosine phosphatase SHP-1, which is expressed predominantly in hematopoietic cells, has been implicated in negative regulation of signaling events induced by receptors for cytokines, growth factors and antigens (12,13). SHP-1 is composed of a central catalytic domain, two Src-homology 2 (SH2) domains at its N-terminus and a C-terminus with tyrosyl phosphorylation sites (14). The best evidence for a critical role for SHP-1 in vivo has come from the motheaten mouse, a naturally existing genetic model for SHP-1 deficiency (1517). Mice homozygotic for the motheaten (me/me) mutation at the SHP-1 locus express no detectable SHP-1 protein. These mice have proven to be a valuable tool for genetic studies to probe the in vivo functions of SHP-1 (18,19). The me/me mice display a multitude of disorders in all hematopoietic lineages. To date, no obvious phenotype has been reported for heterozygotic (me/+) mice.
We and others have previously implicated a role for SHP-1 in TCR-mediated signaling. In an earlier study, we showed that SHP-1 becomes rapidly tyrosyl phosphorylated upon cross-linking of the TCR (14). Recent studies (20,21) have demonstrated that, compared to thymocytes from normal mice, me/me thymocytes are hyper-responsive to TCR stimulation, which is manifested by increased IL-2 production and hyper-proliferation in response to TCR cross-linking. A similar hyper-sensitivity of TCR-mediated signaling was demonstrated by overexpression of dominant negative forms of SHP-1 in Jurkat T cells, which also resulted in enhanced IL-2 production (22). The precise target(s) of SHP-1 remain controversial. Plas et al. suggested Zap-70 as the direct target of SHP-1 (22). In contrast, our data showed that me/me thymocytes display a prolonged activation of Lck and Fyn kinases and increased intracellular tyrosyl phosphorylation of several substrates (20). Regardless of the direct target(s), the above data suggest that SHP-1 is a negative regulator of TCR-mediated signaling and that a lack of SHP-1 causes increased strength of TCR-mediated signals.
Since SHP-1 is implicated in negative regulation of TCR-mediated signaling and the strength of the signal transmitted from the TCR influences T cell maturation, we tested the hypothesis that regulation of TCR-mediated signals by SHP-1 influences thymocyte development by controlling the thresholds for positive and/or negative selection perceived by thymocytes. We hypothesized that a thymocyte expressing a TCR of low avidity, which, due to a weak TCR signal, would normally be `neglected', in the absence of SHP-1, might signal with sufficient strength to be positively selected. Similarly, a thymocyte bearing a TCR of moderate avidity, which would normally be positively selected, might be deleted in the me/me background due to enhanced signals via the TCR. Thus, in the me/me mouse, the `perceived' thresholds for thymic positive and negative selection would be `leftward-shifted' with respect to antigen dose/avidity.
Although, we and others have failed to observe any abnormalities (as assessed by surface marker expression) in overall thymocyte composition in me/me mice (20,21,23,24), it is important to note that analyses of a me/me thymus may not show abnormalities in a steady state since the thymocyte selection process per se is not perturbed, but rather the TCR that are selected have different avidities. If SHP-1 controls signaling thresholds, the average positively selected me/me T cell might express a TCR with lower avidity than the average in a normal mouse. Such an effect would not easily be revealed in me/me mice expressing a large variety of unidentified TCR. However, a role for SHP-1 in thymocyte selection might be detectable if the majority of the thymocytes express a single TCR of a defined affinity (e.g. in a TCR transgenic mouse). Based on this rationale, we adopted a genetic approach, which allowed us to follow the fate of thymocytes in a controlled fashion by monitoring thymocyte populations in which the majority of cells express a specific Tg TCR, in wild-type (+/+), heterozygotic (me/+) or homozygotic motheaten (me/me) backgrounds. We crossed DO11.10 TCR transgenic mice, which express a TCR specific for chicken ovalbumin (OVA) peptide (25) onto the motheaten background. Analyses of thymocytes from the progeny of these mice demonstrates that SHP-1 regulates both positive and negative selection. Data obtained from expression of a dominant negative mutant of SHP-1 in the BYDP hybridoma cell line confirm that SHP-1 helps to control TCR responsiveness in a cell-autonomous manner and suggest that one way SHP-1 negatively regulates TCR signaling might be via the regulation of Lck activity.
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Immunoprecipitation and immunoblotting
Cells (3.5x106) were lysed in 0.35 ml lysis buffer (50 mM TrisHCl, pH 7.6, 150 mM NaCl, 0.5 % NP-40, 1 mM Na3VO4, 10 mM NaF) containing leupeptin (10 µg/ml), aprotinin (1 µg/ml), pepstatin A (1 µg/ml), antipain (1 µg/ml) and PMSF (20 µg/ml). Cell lysates were clarified by centrifugation for 30 min at 100,000 g at 4°C. Then 3 µg of affinity-purified polyclonal rabbit anti-SHP-1 antibodies (14) was added to cleared lysates for 2 h at 4°C. Immune complexes were collected by adding 50 µl of Protein ASepharose (Amersham Pharmacia Biotech, Piscataway, NJ) for 30 min at 4°C, followed by five washes with lysis buffer. Samples were resolved by SDSPAGE and electroblotted onto Immobilon P (Millipore, Bedford, MA). Immunoblots were blocked for 1 h at room temperature with 5% dry milk in TBST (10 mM TrisHCl, pH 8.0, 150 mM NaCl and 0.05% Tween 20) before primary antibodies (anti-SHP-1, polyclonal serum) were added at 1:1000 dilution for 1 h. After three washes in TBST, secondary antibodies (1:7500 dilution; anti-rabbit-horseradish peroxidase; Amersham Pharmacia Biotech) were added for 1 h. After another five washes, immunoblots were developed using enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech).
Lck kinase assays
BYDP cells (5x106) were stimulated as described previously (14) with anti-CD3 (1 µg/ml) plus anti-CD4 (1 µg/ml) antibodies for the indicated times. Stimulated cells were lysed in 0.3 ml Brij 96 lysis buffer (50 mM TrisHCl, pH 7.6, 150 mM NaCl, 10 mM sodium pyrophosphate, pH 7.6, 1% Brij 96, 1 mM Na3VO4 and 10 mM NaF) containing leupeptin (10 µg/ml), aprotinin (1 µg/ml), pepstatin A (1 µg/ml), antipain (1 µg/ml) and PMSF (20 µg/ml). CD4-associated Lck was immunoprecipitated from clarified lysates, prepared as described above, by adding 50 µl of Protein ASepharose for 1 h. The immune complexes were washed 3 times in wash buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM Na3VO4 and 5 mM NaF) and once in kinase reaction buffer (5 mM HEPES, pH 7.4, 5 mM p-nitrophenyl phosphate and 10 mM MnCl2). Kinase reactions were performed in a total volume of 25 µl of kinase buffer containing 5 µCi of [-32P]ATP for 10 min at 30°C. Reaction products were resolved by SDSPAGE, transferred onto Immobilon P as described above and subjected to autoradiography.
IL-2 assay
Ninety-six-well plates were coated with the appropriate concentrations of anti-CD3 antibody overnight at 4°C and washed 3 times with PBS. BYDP-derived cell lines were plated in triplicate at 5x104/well in 200 µl complete medium and incubated for 24 h. Supernatants (125 µl) were harvested and immediately frozen at 70°C. IL-2 bioassays were performed by using IL-2-dependent CTLL cells. CTLL cells were washed 4 times in PBS, plated in 96-well plates (5x103/well in 50 µl complete medium), treated with 50 µl of BYDP supernatant (undiluted, 1:2, 1:4, 1:8, 1:16 and 1:32 dilutions in complete medium) for 20 h and then pulsed for 4 h with 1 µCi of [3H]Thymidine. [3H]Thymidine incorporation was measured as described above. All assays were performed in triplicate.
Flow cytometric analysis
Total thymocytes (2x106) were stained with antibodies to the indicated surface markers in PBS supplemented with 3% BSA and 0.1% sodium azide (FACS juice). All antibodies were used at 2 ng/ml. CD4phycoerythrin, CD8FITC, Vß8biotin (clone MR5-2), CD69biotin and streptavidinCyChrome were purchased from PharMingen (San Diego, CA); CD3biotin and anti-mouseFITC were purchased from Southern Biotechnology (Birmingham, AL). KJ1-26 was kindly provided by M. McDuffie, University of Virginia. To analyze stained thymocytes, 25,000 events were collected on a FACSCalibur instrument calibrated with CaliBRITE beads using CellQuest software for collection and subsequent analyses (Becton Dickinson, Mountain View, CA). Analyses were carried out on live thymocytes (>95%) as defined by forward and side angle scatter. For ex vivo deletion assays, 30,000 events were collected and analyses were carried out on gated live thymocytes (1520%).
Ex vivo deletion assay and Annexin V staining
Ex vivo deletion assays were performed following a previously described protocol (31). Briefly, thymocytes (1x106) were co-cultured with 1x105 A20 B cells in the presence of the indicated concentrations of OVA peptide in complete medium. After 20 h, cells were harvested into FACS juice and analyzed by flow cytometry. For direct assessment of OVA peptide-induced apoptosis, cells were harvested after 8 h, stained with PE-labeled Annexin V (PharMingen) and analyzed by flow cytometry. Gates for the analyses were set so that all thymocytes were included but A20 cells excluded.
Proliferation assay
Proliferation assays were performed as described previously (20). Briefly, for antibody stimulations, 96-well plates were coated with the indicated concentrations of anti-CD3 antibody (145-2c11; Southern Biotechnology, Birmingham, AL) overnight at 4°C and washed 3 times with PBS. Thymocytes were plated in triplicate at 5x104/well in 200 µl complete medium, supplemented with 30 U IL-2/ml and incubated for 72 h before they were pulsed with 1 µCi of [3H]Thymidine for 18 h. [3H]Thymidine incorporation was measured using a cell harvester (Skatron, Sterling, VA). The same procedure was used for antigen stimulation except that the indicated concentrations of OVA peptide (ISQAVHAAHAEINEAGR, synthesized at the Biomolecular Research Facility, University of Virginia; 10 ng/ml = 5.6 nM) were added directly to thymocytes on 96-well plates without pre-coating and without addition of IL-2. For proliferation assays with added antigen presenting cells (APC), 2x106 irradiated (2000 rad) total splenocytes (from a DO11.10 TCR transgenic BALB/c mouse) per well were added to the thymocytes, along with the indicated concentrations of ovalbumin (Sigma, St Louis, MO).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In our previous study, we showed that when stimulated by co-cross-linking of the TCR together with CD4, thymocytes from me/me mice displayed prolonged activation of the src family kinase Lck compared to normal thymocytes (20). We tested whether this was reproduced in our model system and could therefore be attributed to a hyper-sensitivity of the TCRCD4 co-receptor signaling pathway. BYDP cells expressing the different SHP-1 constructs were co-stimulated with anti-CD3 plus anti-CD4 and CD4-associated Lck kinase activity was assayed. All three cell lines showed a similar pattern of Lck activation within 5 min following stimulation. However, the inactivation profile was strikingly different between these lines. In GST alone- or GST-SHP-1 wt-expressing BYDP cells, Lck kinase activity was significantly diminished (by ~50%) within 10 min of stimulation. In contrast, the dominant negative GST-SHP-1 P-expressing cells showed sustained Lck activity (Fig. 1C and D
). This result is similar to our previous observation that thymocytes from me/me mice show prolonged Lck activation upon TCRCD4 stimulation (20). Since expression of a dominant negative mutant of SHP-1 directly causes TCR hyper-sensitivity in a cell-autonomous manner, these results suggest that the primary defect in me/me thymocytes with respect to TCR stimulation is at the level of TCR signaling itself.
Evidence that SHP-1 plays a role in thymocyte development by influencing the thresholds for positive and negative selection
To assess whether the negatively regulatory effect of SHP-1 on TCR signaling translates into a role for SHP-1 in thymocyte development, we examined the progeny of crosses between DO11.10 TCR Tg and me/+ mice. DO11.10 mice express a transgenic TCR specific for a fragment of chicken ovalbumin peptide (amino acids 323339) in the context of I-Ad. Because the antigen specific for the DO11.10 TCR is well defined, doseresponse studies on thymocytes expressing the transgene can be performed to monitor TCR responsiveness either in vivo or ex vivo. We noticed that some of the early generation me/+:Tg and me/me:Tg mice showed several inconsistent and unusual phenotypes with respect to their thymocyte composition (data not shown). However, in later generations, as mice became increasingly congenic, the phenotypes of different animals bearing the same genotype were quite consistent. The observed inconsistent phenotypes in early generations were most likely due to segregating modifier loci in the C57BL/6 background (present in the me/+ mouse used for the initial cross). Therefore, all data presented here are derived from mice of F5 or later generations (four rounds of backcrossing; theoretically, 3% genetic contribution by C57BL/6).
Effects in homozygotic me/me TCR Tg mice
Thymocytes from the various mice derived from intracrosses were analyzed for their surface marker expression (Fig. 2 and Table 1
). As expected from previous studies (20,21,23,24), thymuses from +/+:DO11.10 TCR Tg (+/+:Tg) mice showed a normal composition with respect to the percentages of DN (CD4CD8), DP (CD4+CD8+) and SP (CD4+CD8 and CD4CD8+) subpopulations (Fig. 2A
). A similar (normal) composition was observed for non-Tg thymi, independent of their genotype at the SHP-1 locus (Fig. 2D
and bottom half of Table 1
). These data are consistent with our previous observation that me/me mice have overall normal thymocyte subpopulations (20). However, in our analyses of a large number of mice, we observed that in the presence of the DO11.10 transgenic TCR, thymocytes from me/me mice revealed abnormalities, manifested as the following unusual phenotypes.
|
|
|
To further characterize the thymocyte subpopulations, thymocytes were triple-stained for CD4, CD8 and CD3 (CD4 versus CD3; Fig. 2EH). The majority of the CD4+ SP thymocytes in the +/+:Tg as well as the me/me:Tg mice were CD3high (and CD69high, data not shown), indicating that these are indeed mature, positively selected thymocytes. Analyses of TCR ß expression on these CD4+ SP cells showed that they express the transgenic Vß8 chain (CD4 versus Vß8; Fig. 2IM
) (see below for comparison with staining by KJ1-26, a clonotypic anti-DO11.10 TCR antibody which recognizes the transgene-specific
and ß chains of the TCR).
Our results suggest that, in addition to helping to set the threshold for negative selection, SHP-1 also plays a role in setting the threshold which determines whether a cell is `neglected' or positively selected. In the absence of SHP-1, both thresholds are lowered leading to enhanced negative selection and `leftward-shifted' positive selection.
TCR+ DN cells.
In addition to the relative increase in CD4+ SP cells, thymocytes from me/me:Tg mice also showed an ~3- to 5-fold increase in the percentage of DN cells, which lack both CD4 and CD8 expression (Fig. 2 C). Interestingly, we found that, unlike in normal mice, the majority of these DN thymocytes in me/me:Tg mice were CD3+ and Vß8+ (Fig. 2G and L
). These data indicated that these cells were not `typical' DN cells or NK cells arising in the me/me background. Since TCR expression on these cells was medium to high and they were also CD69high (data not shown), it is likely that these TCR+ DN thymocytes were positively selected or at least had been stimulated via the TCR, either in the absence of co-receptors or in the presence of CD4 and CD8 whose surface expression was then lost during further maturation. At the time point that thymic compositions were analyzed (1519 days post-natal), the majority of the DN cells in me/me:Tg expressed the TCR and was therefore part of this unusual subpopulation, only a relatively small fraction of thymocytes were `true' DN cells.
To analyze the thymocytes not only for expression of the transgenic Vß8 chain, but also for expression of the complete transgenic TCR ( and ß chain), cells were stained with KJ1-26, a clonotypic anti-DO11.10 TCR antibody (Fig. 3
). For +/+:Tg thymocytes, staining with KJ1-26 overlapped the Vß8 staining (Fig. 3A
), indicating that all of the cells express both the
and ß chain of the transgenic TCR. With respect to Vß8 staining per se, me/me:Tg thymocytes showed an increase in Vß8high and a decrease in Vß8med staining (Fig. 3B and C
). This is consistent with the increase in CD4+ SP and the decrease in DP cells caused by the enhanced negative and `leftward-shifted' positive selection in me/me:Tg mice. In general, me/me:Tg mice also displayed similar staining for Vß8 and KJ1-26. We observed some variation in different mice with the me/me:Tg genotype, most likely due to slight genetic variations. About 50% of the me/me:Tg mice showed an almost identical profile for Vß8 and KJ1-26 staining (Fig. 3B
), whereas the other half displayed a small decrease of KJ1-26med staining compared to Vß8med (Fig. 3C
), indicating that a small portion of thymocytes from these mice expressed medium levels of a TCR composed of the transgenic ß chain paired with endogenous
chains.
|
Thymocytes from me/me mice execute negative selection at lowered antigen concentrations
The above data on DO11.10 TCR Tg mice suggested that there was a change in positive and negative thymocyte selection thresholds in me/me progeny compared with +/+ mice, which was observable even in the absence of the TCR-specific OVA peptide. To further test the hypothesis that SHP-1 helps control positive/negative selection by regulating the strength of TCR-mediated signals, we analyzed thymocyte responsiveness to various dosages of OVA peptide. We chose not to administer peptide in vivo by injection since the increased numbers of macrophages in the me/me mouse would add uncontrollable variables to the experiment, such as clearance, delivery and presentation of the peptide. Instead, we performed ex vivo assays using primary thymocytes from mice of the various genotypes.
Previously, it has been shown that exposure of immature thymocytes to their specific antigen ex vivo leads within a day to deletion due to negative selection (31). We hypothesized that if SHP-1 plays a regulatory role in this process, the critical concentration of antigen needed for negative selection should be lowered in the absence of SHP-1. Thymocytes from +/+:Tg and me/me:Tg mice were incubated with increasing concentrations of OVA peptide in the presence of A20 cells as APC and thymic composition was examined the following day. In the absence of A20 cells, no deletion was observed at concentration 100 nM. As described previously (31) in the presence of A20 cells, there was `spontaneous deletion' even in the absence of antigen; ~4050% in the me/me:Tg and 3040% in +/+:Tg thymocyte populations. Since this slightly increased deletion of me/me:Tg thymocytes is dependent on the presence of the antigen presenting A20 cell, it might have been caused by stimulation with a peptide derived from the A20 cells. In the hyper-sensitive me/me background, this stimulation could have been strong enough to cause enhanced negative selection. As shown in Fig. 4
(A and B), thymocytes from +/+:Tg mice (top row of each panel in Fig. 4A
) do not show deletion of the immature CD4+CD8+ DP population <7.510 nM OVA peptide, consistent with the previous report (31). In contrast, me/me:Tg thymocytes (bottom row of each panel in Fig. 4A
) displayed significant OVA-specific deletion even in the 17.5 nM range. In this assay, negative selection can be observed not only as a decrease in the DP subpopulation, but also as a shift within the DP profile from CD4highCD8high towards CD4lowCD8low as a transitional stage towards death (31). We then confirmed that the observed loss of DP thymocytes reflected actual negative selection of these thymocytes, rather than a down-modulation of the co-receptors CD4 and CD8 caused by stimulation of the TCR (33). Thymocytes from +/+:Tg and me/me:Tg mice were incubated with increasing concentrations of OVA peptide presented by A20 cells and induced cell death was measured directly by Annexin V staining. Again, me/me:Tg thymocytes were hyper-responsive and exhibited cell death due to negative selection at much lower concentration of OVA peptide than +/+:Tg thymocytes (Fig. 4C
). These results, showing increased negative selection in the me/me background confirm that SHP-1 acts in a cell-autonomous manner to set the threshold for negative selection and that in the absence of SHP-1, a decreased dose of antigen is needed to induce cell death, i.e. a `leftward-shift' in the dose response is observed. These ex vivo deletion data are fully consistent with the increased negative selection observed in vivo.
Hyper-sensitive proliferative response of thymocytes from me/me TCR Tg to specific antigen
The differences in thymocyte composition between +/+:Tg and me/me:Tg mice suggested that negative and maybe positive selection are affected by the absence of SHP-1 as well as a possible hyper-proliferation of the CD4+ SP subpopulation. To test the responsiveness of mature, positively selected thymocytes, we measured their proliferative response to anti-CD3 stimulation. Similar to our previous observations using thymocytes from non-Tg mice (20), we observed hyper-sensitivity of the me/me thymocytes compared to the +/+ or me/+ thymocytes, which was manifested by an ~1.5- to 2-fold lower EC50 (~250 versus 400 ng/ml) (Fig. 5A). The data are presented as percentage of maximal stimulation, since the absolute values also depend on the number of responding cells. Based on the flow cytometric profiles (see above), this number is expected to differ between mice of the various genotypes. In general, thymocytes from me/me mice incorporated 1.52.5 times more radioactivity than +/+ or me/+ thymocytes. We then asked how these thymocytes respond to their specific antigen, the OVA peptide. Total thymocytes were incubated with increasing amounts of OVA peptide and proliferation was measured (Fig. 5B
). As in the case of anti-CD3 stimulation, me/me:Tg thymocytes were hyper-sensitive compared with +/+:Tg thymocytes, with an ~2- to 2.5-fold lower EC50 observed (~285 versus 675 ng/ml). Interestingly, in contrast to anti-CD3 stimulation where +/+ and me/+ thymocytes were indistinguishable, thymocytes from me/+ mice showed an intermediate responsiveness to OVA peptide with an EC50 between me/me and +/+. This dosage-dependent epistatic interaction between the SHP1 and TCR loci provides additional genetic evidence that the two proteins act in the same pathway.
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
These data and reports that thymocyte selection is influenced by the signal strength mediated via the TCR led us to hypothesize that SHP-1 might play a role in this process by affecting the signaling thresholds for positive and negative selection. To test our hypothesis in vivo, we used a genetic model and crossed the motheaten mutation into the DO11.10 transgenic TCR background. Flow cytometric analyses of progeny from these crosses revealed a number of alterations in the thymocyte phenotypes in me/me:Tg mice compared to +/+:Tg mice. First, there was a greatly reduced cellularity which is at least to a large part due to a dramatic loss of DP thymocytes in the me/me:Tg mice. A decreased number of DP cells can have five possible reasons. (i) Thymocytes arrest at the DN stage before they mature to DP cells. However, in this case, we would expect an increase in the absolute number of DN cells, which we did not observe. In contrast, the DN population was diminished (see below). (ii) Thymocytes do not expand at the DP stage. A failure to proliferate would be followed by a similar decrease in the number of SP cells. However, this was not detected in the me/me:Tg mice; if at all, me/me thymocytes seemed to hyper-proliferate (see below). (iii) A decrease in thymic precursor cells causing an overall diminished thymic cellularity. However, since this would affect all thymocytes the ratios between the different subpopulations (DN, DP, CD4+ SP and CD8+ SP) would not be changed. (iv) Failure to express CD4 and CD8 during the transition from DN to DP stage. It is possible that in the absence of SHP-1, a thymocyte at the transition from DN to DP (TCR+ CD4CD8low) perceives a signal mediated via the TCR as strong enough to down-regulate surface expression of CD4 and CD8, thereby generating TCR+ DN cells as described for TCR cross-linking studies of TCR+CD4CD8low cells (32). Interestingly, a TCR+ DN population was observed in the me/me:Tg mice (see below). Since these cells never enter the DP stage, the DP population would be decreased at the same time. However, the limited number of TCR+ DN cells (107) cannot by itself be the only reason for the dramatic loss in the DP population [12x107 (+/+) versus 1.8x107 (me/me)]. (v) Increased cell death of DP thymocytes due to negative selection.
The DP population remaining in the me/me:Tg mice showed a shift from CD4highCD8high towards CD4lowCD8low. There are two possible causes for the appearance of such a population: (i) these thymocytes down-regulated their surface expression of CD4 and CD8 in response to a TCRCD4 stimulation as it was observed in the ex vivo deletion assays (Fig. 4A) or (ii) because of their low surface expression of CD4 and CD8, these cells escaped the increased ongoing negative selection and are therefore enriched in the me/me:Tg mice. In contrast to the decreased number of DP cells, the absolute number of CD4+ SP thymocytes stayed relatively constant. Moreover, an unusual TCR+ DN population was observed. These data, indicating increased negative selection in me/me:DO11.10 Tg mice, together with studies showing that thymocytes from these mice are hyper-sensitive to their specific antigen when examined in ex vivo deletion assays support our hypothesis that SHP-1 helps to set the threshold for negative selection and that, in its absence, the threshold is lowered.
The lack of effect on the number of CD4+ SP thymocytes despite the dramatic loss of DP thymocytes can have two possible, not mutually exclusive, reasons. (i) A subpopulation of thymocytes which would have been neglected under normal conditions (in a +/+:Tg) was positively selected. Since these mature CD4+ SP cells were observed without exposure to the TCR-specific OVA peptide, positive selection in me/me:Tg mice must have, at least partially, occurred following stimulation by endogenous peptide(s) of low avidity for the transgenic TCR. Under normal conditions, such stimulation would have led to neglect due to insufficient stimulation; however, in the absence of SHP-1, a lowered threshold for positive selection would enable antigens with `normally' too low affinity to positively select thymocytes expressing the Tg TCR. (ii) The CD4+ SP thymocytes hyper-proliferated following positive selection leading to a selective expansion of this subpopulation. Based on our ex vivo proliferation assays which showed a hyper-sensitivity of me/me:Tg thymocytes to antigen-specific stimulation, it is conceivable that at least part of the decreased DP population was compensated at the CD4+ SP stage by hyper-proliferation. However, cell cycle studies showed that the percentages of CD4+ SP thymocytes in G0/G1, S and G2/M phase were similar between +/+, me/+ and me/me DO11.10 TCR Tg mice indicating comparable in vivo proliferation (J.D.Carter and U.Lorenz, unpublished observation). Therefore, it is very likely that the threshold for positive selection also was lowered in the absence of SHP-1, especially in the light of two very recent reports showing increased positive selection, one of which examined me/me mice expressing a MHC class I-restricted transgenic TCR (35) and one of which used mice expressing a dominant negative mutant of SHP-1 in the context of a MHC class II-restricted transgenic TCR (36).
In addition to the phenotypes described above, thymuses from me/me:Tg mice contained an unusual population of TCR+ DN thymocytes. There are several possible explanations for the appearance of these cells. These cells might have been derived from a population (TCR+CD4CD8low) in transition from DN to DP which, due to the absence of SHP-1, received a strong enough signal mediated via the TCR to down-regulate surface expression of CD4 and CD8. Such a mechanism has been observed in ex vivo studies (32). Another possibility is that these cells were positively selected but then down-regulated CD4 expression. Alternatively, in the absence of SHP-1, the TCR alone could send a signal of sufficient strength to positively select cells which express neither CD4 nor CD8. Under normal conditions, TCR+ DN would not receive a signal of sufficient strength and be neglected. It is also possible, that TCR+ DN thymocytes represent a distinct lineage in Tg mice that accumulates under these specific conditions, as seen previously in male HY-TCR Tg mice (37). Further studies will be necessary to distinguish between these possibilities.
It is striking that the dramatic decrease of DP thymocytes due to negative selection observed here was not detectable in a non-Tg me/me mouse. There are two possible, not mutually exclusive, reasons for this observation. (i) The number of potentially different TCR with their various avidities in a non-TCR Tg mouse might not allow us to uncover such an effect because the deleted thymocytes would be continuously replaced. In contrast, in TCR Tg mice in which a major fraction of the thymocytes carry a TCR of the same avidity, an increase in deletion would be more easily detected. (ii) One of the differences between a Tg TCR and an endogenous TCR is the early expression of high levels of the Tg TCR as evidenced by the absence of a TCRlow population (cf. Figs 2EG and 2H). It is conceivable that negative selection in a TCR Tg mouse occurs at an earlier developmental state within the DP population compared to a non-TCR Tg mouse, causing a greater apparent loss of DP thymocytes. It is important to stress that our data indicate that the `normal' thymocyte composition in me/me mice only reflects the `steady-state' level of the overall thymocyte population, but does not imply that TCR signaling with respect to thymocyte selection is normal in me/me mice. Instead our data predict the average affinity of a TCR for its antigen in me/me mice is lower than in normal mice. These differences are revealed only in the sensitized background of TCR Tg mice.
In previous studies, we and others failed to observe any abnormal/intermediate phenotype in heterozygotic me/+ mice, indicating that one wild-type allele of SHP-1 is sufficient to produce a normal phenotype. However in this study, we observed an intermediate phenotype for me/+ mice compared to +/+ and me/me mice when analyzed for thymic composition (Table 1 and Fig. 2
), as well as when assayed for proliferative response to its specific antigen (Figs 5 and 6
). This epistatic interaction between the SHP-1 and the TCR loci provides further genetic evidence that SHP-1 and the TCR are part of the same signaling pathway. Detection of this phenotype is most likely due to the sensitized background provided by the use of a TCR transgene, which allows us to reveal subtle differences in signal strengths. Similar dosage effects of signaling molecules on thymocyte selection have been elegantly demonstrated by Perlmutter and colleagues using different copy numbers of an Lck transgene (38). This is particularly interesting, since our previous studies (20) and data present here indicate that Lck might be at least one of the targets by which SHP-1 exerts its regulatory function in TCR signaling.
In addition, the fact that we observed an intermediate phenotype for OVA peptide stimulation, but not for anti-CD3 cross-linking, emphasizes the differences between non-physiological antibody cross-linking and antigen-specific stimulation by APC. CD3 cross-linking biases towards signals delivered by TCR stimulation, whereas under physiological conditions, signals are delivered by both the TCR and the CD4MHC complex. The observed difference is of particular interest since our data implicate the CD4-associated Lck as a target for SHP-1. A similar distinction was noted previously in a CD45 T cell line which was reconstituted with different isoforms of CD45. Certain functional differences between these isoforms were revealed upon antigen-specific stimulation but not upon anti-TCR cross-linking (39).
Interestingly, in two recent reports which addressed the role of SHP-1 in thymocytes development, SHP-1 seemed to regulate only positive selection but no change in negative selection was observed. Most likely, these differences are due to the genetic background of the mice that were analyzed and the different transgenic TCR that were used. For example, Johnson et al. studied the progeny of C57BL/6J mice crossed to C57BL/10 mice in the context of a MHC class I-restricted TCR (35), whereas Plas et al. analyzed progeny of cross between C57BL/6 and B6.AKR mice using a MHC class II-restricted TCR (36). In our studies, we used a MHC class II-restricted TCR in a >97 % congenic BALB/c background generated by at least five rounds of backcrosses. Since the endogenous antigens which `normally' cause positive selection of these transgenic TCR are unknown, it is impossible to identify the exact differences between the mice used in the three studies. However, it is conceivable that there are differences in affinities which, in turn, affect the sensitivity of the individual mouse to the loss of a negative regulator such as SHP-1. Interestingly in a recent study, it was reported that motheatenviable (mev/mev) mice, which carry a different mutated allele of SHP-1 encoding a protein with decreased phosphatase activity, show increased deletion in response to an endogenous superantigen (40). Together with our studies, this provides further evidence that SHP-1 is involved in setting the threshold for negative selection. As discussed above, we observed that the me/+ mouse produces an intermediate phenotype between +/+ and me/me mice with a more detectable effect on positive than on negative selection (~50% increase of the number of CD4+ SP cells compared to 25% decrease of DP cells; Table 1). In the Plas et al. study, the loss of SHP-1 activity was generated by expression of a dominant negative mutant of SHP-1 in mice which, according to the authors, showed a 10 and 25% increase in total SHP-1 expression. Therefore, it is possible that their observation that only positive selection was affected might be due a decrease but not a total loss in SHP-1 activity, thereby more mimicking a me/+ mouse than a me/me mouse.
SHP-1 has an analogous function in B cells, where it sets the threshold for B cell receptor signaling (41). In the me/me mouse, this signaling defect leads to a severe disruption of B cell development. In contrast, overall T cell development appears normal in me/me mice (20,2224). It is well established that src family kinases play a major role in lymphocyte development (reviewed in 1,2) and our data strongly suggest that SHP-1 exerts its function as a negative regulator of TCR signaling by regulating Lck activity. Another protein phosphatase, CD45, has been shown to be necessary for activation of src family kinases (42,43). Interestingly, CD45 knock-out mice (10) display a phenotype almost the converse of the motheaten phenotype with a strong defect in thymocyte development and a minor defect in B cell development, the latter detectable only in the sensitized context of B cell receptor transgenic mice (44). Since it has been shown that some of the B cell defects in motheaten mice can be rescued by lack of CD45 (45), it is likely that regulation of antigen receptor signaling via the downstream src family kinases is determined both by SHP-1 and CD45.
SHP-1-deficient mice exhibit an early involution of their thymus, most notable in mev/mev mice. Transplantation experiments of normal and mev/mev bone marrow suggested that a homing defect of the pro-thymocytes was the cause for the early involution observed in motheaten mice (46). However, our data suggest an alternative or additional reason. Due to the increased deletion in me/me mice, more thymocytes have to flux through the thymus to sustain a normal total thymocyte number. Eventually, this would lead to a depletion of precursors and, if the mouse lives long enough, result in an early involution of the thymus. This is consistent with our observation that there are very few `typical' DN thymocytes in me/me:Tg mice.
Although our data demonstrate a role for SHP-1 in regulating the thymocyte selection process, the precise molecular mechanism by which SHP-1 exerts such regulation is unclear. One potential, previously described binding partner for SHP-1 at the cell surface is CD5 (21,47). Co-cross-linking of CD5 and the TCRCD3 complex compared to TCRCD3 alone leads to a decrease in tyrosyl phosphorylation of a number of substrates (47). Moreover, CD5 has been implicated in negative regulation of TCR signaling, based on studies of TCR Tg mice in a CD5-deficient background. Indeed, such CD5-deficient mice show changes in their thymocyte selection profiles (11) that resemble our observations of SHP-1-deficient mice. In this regard, the role of CD5 in T cells might be analogous to that of CD22 in B cell signaling (4851). Alternatively, it is well documented that SHP-1 becomes tyrosyl phosphorylated rapidly following T cell activation (14). This indicates its proximity to the PTKs that become activated upon TCR engagement and tyrosyl phosphorylation might be a possible means of recruitment. Our observations (20 and the data presented above) strongly suggest that SHP-1 functions upstream of src family kinases such as Lck and Fyn. Since Zap-70 is downstream of Lck in the TCR signaling cascade, it is feasible that the previously described regulation of Zap-70 activity by SHP-1 (22) is, in fact, due to the regulation of Lck by SHP-1 with Zap-70 being affected indirectly. Alternatively, both Lck and Zap-70 could be direct targets of SHP-1. Given the previously established role for Lck in regulating TCR-mediated events during thymocyte development, it is possible that SHP-1 may regulate thymocyte selection events by directly controlling activation of Lck. However, additional evidence addressing whether Lck is a direct or a downstream target remains to be supplied. Further studies will be necessary to identify the specific downstream molecule(s) through which SHP-1 exerts its regulation of the TCR signal strength during thymocyte development. Since the selection of an appropriate repertoire of T cells is critical for normal immune responses and for preventing autoimmune diseases and immunodeficiencies, it will be important to identify these targets of SHP-1.
![]() |
Acknowledgments |
---|
![]() |
Abbreviations |
---|
APC antigen-presenting cell |
DP double positive |
DN double negative |
GST glutathione-S-transferase |
PTK protein tyrosine kinase |
SH2 Src-homology region 2 |
SP single positive |
Tg transgenic |
![]() |
Notes |
---|
Received 30 June 1999, accepted 1 September 1999.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|